Semi-Solids

Groupe PARIMA develops and manufactures semi‑solid drug products using a QbD approach.

Inner banner
A partner for predictable progress

Predictable outcomes at every scale

Semi‑solid formulations demand repeatable processes and controlled execution to remain viable at scale. Groupe PARIMA supports development and manufacturing through process control, fit‑for‑purpose analytics, and documentation that enables scientific decisions.

Performance that holds at scale

Consistency at scale depends on controlling the process conditions that define semi‑solid performance. We link process control, targeted analytical support, and documentation to strengthen GMP readiness and maintain long‑term supply continuity.

CONSISTENT PERFORMANCE AT SCALE

We control processing parameters during scale‑up that affect rheology and batch uniformity.

CHANGE-READY CONTROL STRATEGY

Using QbD principles, we define and maintain the control strategy across the product lifecycle.

IN‑VITRO RELEASE TESTING

IVRT methods using Franz diffusion and enhancer cells to assess performance and comparability.

Scalable processes by design

We use QbD from the start to define CQAs, identify CPPs affecting viscosity, uniformity, and API release, and build a scalable process supported by the right documentation.

Card 01

Formulation Robustness

We run product compatibility studies to reduce the impact of the formulation and packaging components. We also support leachable and extractable studies.  

Card 02

Critical Quality Attributes

Translate target product profile into CQAs that matter most for semi-solids, such as consistency, uniformity, stability, and performance-relevant characteristics.

Card 03

Critical Process Parameters

Identify process parameters that influence viscosity behavior, uniformity, and API release, with specific attention to mixing and filling conditions.

Card 04

Consistency across the lifecycle

Apply control strategy to maintain consistent semi‑solid process and product performance throughout the lifecycle and support process validation and routine production.

Card 05

Establish a scalable process

We define a reproducible process suitable for clinical, exhibit, and commercial production, supported by fit-for-purpose analytical methods aligned with semi-solid scale-up.

Dosage Form capabilities

Groupe PARIMA applies dosage-form-specific development and manufacturing capabilities to keep critical attributes consistent as scale-up, equipment, and demand evolve.

Cream
Cream

We develop oil-in-water and water-in-oil creams using high-shear homogenization, validated for viscosity, droplet size, and phase stability across shelf life.

  • Emulsion stability under temperature cycling.
  • Homogeneous distribution of poorly soluble APIs.
  • Optimization of pH and preservative systems for microbial protection.
Ointment
Ointment

We develop ointments with controlled API solubilization or dispersion and consistent texture and in vitro permeation testing as needed.

  • Choose the right oleaginous or absorption base.
  • Resolve issues with API sedimentation or crystallization.
  • Minimize grittiness and ensure consistent texture and application profile.
Lotion
Lotion

We develop lotions with controlled flow properties and stable emulsions, using a scale-ready approach that maintains uniformity through optimized mixing, shear, and cooling profiles.

  • Enhance spreadability without compromising API stability.
  • Select non-irritant emulsifiers and humectants for sensitive applications.
  • Ensure physical stability and microbial robustness in low-viscosity systems.
Gel
Gel

We develop gels with highly sensitive to formulation conditions such as polymer level and pH, which is why control matters early. Our team applies IVRT to support formulation optimization and strengthen decision-making.

  • Select gelling agents based on viscosity and drug release.
  • Resolve API-polymer interactions that may impact clarity or stability.
  • Ensure batch-to-batch rheological consistency using detailed viscosity and texture analysis.

Our Services

We connect development, analytical support, and GMP execution to manage semi-solid variables proactively and keep timelines moving.

01
Layer_1 (3)-1
Product Development

Formulate and optimize semi-solids with tight control of texture, uniformity, and stability.

02
Icons (1)-2
Analytical Services

Use fit-for-purpose testing to confirm consistency, performance, and stability as you scale-up.

03
Icons (2)-1
Manufacturing & Packaging

Manufacture and fill semi-solids reliably by controlling mixing, temperature, shear, and filling conditions.

We ensure semi-solid shelf life by controlling key risk drivers from day one, tightening process controls, and confirming performance through fit-for-purpose stability studies.

Resources

Access practical guidance for semi‑solid development and manufacturing that impacts shelf life.

Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development
Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development

Contact Us

De-risk your semi-solid products.

Tell us about your dosage form and current stage, and discuss shelf-life drivers, process controls, and a practical path to consistent manufacturing.